NEW YORK (GenomeWeb News) — The US Centers for Disease Control and Prevention has awarded $11.4 million to Cepheid, Nanogen, and two other companies developing “quick” and “accurate” field-deployable tests to diagnose H5N1 avian flu and other influenza viruses, the CDC said yesterday.
 
The CDC said it intends to work with the US Food and Drug Administration to help tests developed from the program to receive FDA clearance and be ready for commercialization “within two to three years.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.